Cargando…

Correction: Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics

Detalles Bibliográficos
Autores principales:	Carter, Bing Z., Mak, Po Yee, Tao, Wenjing, Ayoub, Edward, Ostermann, Lauren B., Huang, Xuelin, Loghavi, Sanam, Boettcher, Steffen, Nishida, Yuki, Ruvolo, Vivian, Hughes, Paul E., Morrow, Phuong K., Haferlach, Torsten, Kornblau, Steven, Muftuoglu, Muharrem, Andreeff, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10188521/ https://www.ncbi.nlm.nih.gov/pubmed/37193700 http://dx.doi.org/10.1038/s41408-023-00857-z

Ejemplares similares

Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics
por: Carter, Bing Z., et al.
Publicado: (2023)

Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias
por: Nishida, Yuki, et al.
Publicado: (2023)

Low carbohydrate diet prevents Mcl-1-mediated resistance to BH3-mimetics
por: Rubio-Patiño, Camila, et al.
Publicado: (2016)

Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia
por: Moujalled, Donia M., et al.
Publicado: (2023)

First MCL-1-selective BH3 mimetics as potential therapeutics for targeted treatment of cancer
por: Besbes, S, et al.
Publicado: (2015)

Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors
por: Zhang, Shengzhe, et al.
Publicado: (2018)

Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugs
por: Diepstraten, Sarah T., et al.
Publicado: (2023)

Increased MCL1 dependency leads to new applications of BH3-mimetics in drug-resistant neuroblastoma
por: Jacob, Maureen, et al.
Publicado: (2023)

AT101 [(-)-Gossypol] Selectively Inhibits MCL1 and Sensitizes Carcinoma to BH3 Mimetics by Inducing and Stabilizing NOXA
por: Mallick, David J., et al.
Publicado: (2020)

Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML
por: Ewald, Larissa, et al.
Publicado: (2019)

Inhibition of MARCH5 ubiquitin ligase abrogates MCL1-dependent resistance to BH3 mimetics via NOXA
por: Subramanian, Aishwarya, et al.
Publicado: (2016)

Mitochondrial apoptosis and BH3 mimetics
por: Dai, Haiming, et al.
Publicado: (2016)

BH3 Mimetics in Hematologic Malignancies
por: Klener, Pavel, et al.
Publicado: (2021)

Cyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics
por: Choudhary, Gaurav S., et al.
Publicado: (2015)

MCL-1 Inhibition by Selective BH3 Mimetics Disrupts Mitochondrial Dynamics Causing Loss of Viability and Functionality of Human Cardiomyocytes
por: Rasmussen, Megan L., et al.
Publicado: (2020)

The MCL-1 BH3 Helix is an Exclusive MCL-1 inhibitor and Apoptosis Sensitizer
por: Stewart, Michelle L., et al.
Publicado: (2010)

Inhibition of the Anti-Apoptotic Bcl-2 Family by BH3 Mimetics Sensitize the Mitochondrial Permeability Transition Pore Through Bax and Bak
por: Patel, Pooja, et al.
Publicado: (2021)

Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner()()
por: Kiprianova, Irina, et al.
Publicado: (2015)

On BH3 Mimetics and Ca(2+) Signaling
por: Ferdek, Pawel E., et al.
Publicado: (2017)

BET-inhibitors as sensitizers for BH3-mimetics
por: Ishida, Chiaki Tsuge, et al.
Publicado: (2017)

BH3 Mimetics for the Treatment of Prostate Cancer
por: Wolf, Philipp
Publicado: (2017)

The application of BH3 mimetics in myeloid leukemias
por: Parry, Narissa, et al.
Publicado: (2021)

BH3 mimetic-elicited Ca(2+) signals in pancreatic acinar cells are dependent on Bax and can be reduced by Ca(2+)-like peptides
por: Ferdek, Pawel E, et al.
Publicado: (2017)

The deubiquitinating enzyme OTUD1 antagonizes BH3-mimetic inhibitor induced cell death through regulating the stability of the MCL1 protein
por: Wu, Lanqin, et al.
Publicado: (2019)

Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models
por: Cucarull, Blanca, et al.
Publicado: (2020)

Noxa and Mcl-1 expression influence the sensitivity to BH3-mimetics that target Bcl-xL in patient-derived glioma stem cells
por: Vera, Mariana Belén, et al.
Publicado: (2022)

BH3-mimetics: recent developments in cancer therapy
por: Townsend, Paul A., et al.
Publicado: (2021)

Sensitivity of canine hematological cancers to BH3 mimetics
por: Jegatheeson, Selvi, et al.
Publicado: (2022)

Hypericin, a potential new BH3 mimetic
por: Doroshenko, Anastasia, et al.
Publicado: (2022)

Downregulation of MCL-1 and upregulation of PUMA using mTOR inhibitors enhance antitumor efficacy of BH3 mimetics in triple-negative breast cancer
por: Li, Haolong, et al.
Publicado: (2018)

Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia
por: Moujalled, Donia M., et al.
Publicado: (2018)

A direct comparison of selective BH3-mimetics reveals BCL-X(L), BCL-2 and MCL-1 as promising therapeutic targets in neuroblastoma
por: Bierbrauer, Annika, et al.
Publicado: (2020)

A same‐day assay predicts apoptotic response to combined BCL‐2 and MCL‐1 BH3‐mimetic targeting in multiple myeloma cells
por: Grundy, Martin, et al.
Publicado: (2020)

MiRNA-16-1 Suppresses Mcl-1 and Bcl-2 and Sensitizes Chronic Lymphocytic Leukemia Cells to BH3 Mimetic ABT-199
por: Ashofteh, Nooshin, et al.
Publicado: (2022)

Photocatalytic proximity labelling of MCL-1 by a BH3 ligand
por: Beard, Hester A., et al.
Publicado: (2019)

MCL-1ES Induces MCL-1L-Dependent BAX- and BAK-Independent Mitochondrial Apoptosis
por: Kim, Jae-Hong, et al.
Publicado: (2013)

Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and re-sensitizes acute myeloid leukemia to BCL-2 inhibition
por: Carter, Bing Z., et al.
Publicado: (2020)

The BH3 Mimetic Obatoclax Accumulates in Lysosomes and Causes Their Alkalinization
por: Stamelos, Vasileios A., et al.
Publicado: (2016)

The Role of BH3-Mimetic Drugs in the Treatment of Pediatric Hepatoblastoma
por: Lieber, Justus, et al.
Publicado: (2015)

Overcoming EMT-driven therapeutic resistance by BH3 mimetics
por: Keitel, Ulrike, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_raum563sohu3u3v2982bj80f0v